| Name | Title | Contact Details |
|---|
Catalyst + Talent. Our name combines these ideas. From drug and biologic development services to delivery technologies to supply solutions, we are the catalyst for your success. With over 80 years of experience, we have the deepest expertise, the broadest offerings, and the most innovative technologies to help you get more molecules to market faster, enhance product performance and provide superior, reliable manufacturing and packaging results. Catalent develops. With our broad range of expert services we drive faster, more efficient development timelines to help you take more molecules to market and create more effective products. Catalent delivers. As the world leader in drug delivery innovations, we have a proven record of enhancing bioavailability, solubility and permeability, improving ease and route of administration, and increasing patient compliance for better treatments. Catalent supplies. Globally positioned to serve all your manufacturing and commercial packaging needs, we provide integrated solutions to take your product from design, to clinical trial, to plant, and to pharmacy.
Hospice of Central Michigan, Inc. is a Mount Pleasant, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MG&G Advertising is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MDInfo is a Denver, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
OncoCellMDx is a privately held company dedicated to the development and commercialization of novel diagnostic tests utilizing proprietary technologies created at Harvard Medical School. In particular, we have developed a noninvasive blood-based immunogenomic assays that will aid the physician to better understand the underlying pathology. The first product is for assessing the severity of prostate cancer. Other oncology indications as well as non-oncology indications are part of our pipeline. The assay is based on examining specific transcription levels between phagocytic and non-phagocytic cells. This proprietary technology and algorithm has allowed us to not only detect disease but to also, and more importantly, guide the physician as to the grade and aggressiveness of the disease. Our mission is to provide clinicians with quantifiable results that allows professionals to make timely and much more directed medical decisions.